PMID- 19921414
OWN - NLM
STAT- MEDLINE
DCOM- 20100715
LR  - 20211020
IS  - 1573-2576 (Electronic)
IS  - 0360-3997 (Linking)
VI  - 33
IP  - 3
DP  - 2010 Jun
TI  - Prolonged administration enhances the renoprotective effect of pentoxifylline via 
      anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.
PG  - 137-43
LID - 10.1007/s10753-009-9167-6 [doi]
AB  - The beneficial effects of pentoxifylline (PTX), which has an anti-inflammatory 
      and renoprotective effect in diabetic nephropathy, are not completely understood. 
      This study investigates whether prolonged administration of PTX (40 mg/kg, per 
      oral) is effective in streptozotocin-induced diabetic nephropathy. The amount of 
      urinary protein was higher in the diabetic rats than in the control rats. The 
      amount remained unchanged after 4 weeks and decreased after 8 weeks of PTX 
      treatment. Accumulation of monocyte chemoattractant peptide-1 (MCP-1) and mouse 
      monoclonal anti-monocyte/macrophage antibody (ED-1) positive cells was higher in 
      untreated diabetic rats than in the control rats. PTX administration ameliorated 
      the urinary MCP-1 excretion and interstitial infiltration of ED-1 positive cells 
      at 4 weeks. Further, in diabetic rats, administration of PTX for 4 weeks 
      inhibited the renal inflammatory reaction, and when administration for 8 weeks, 
      it prevented proteinuria. These findings support the hypothesis that prolonged 
      administration enhances the protective effects of PTX.
FAU - Han, Kum Hyun
AU  - Han KH
AD  - Department of Internal Medicine, Inje University College of Medicine Ilsan-Paik 
      Hospital, Goyang, Korea.
FAU - Han, Sang Youb
AU  - Han SY
FAU - Kim, Han Seong
AU  - Kim HS
FAU - Kang, Young Sun
AU  - Kang YS
FAU - Cha, Dae Ryong
AU  - Cha DR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (CD68 protein, rat)
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (RNA, Messenger)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Antigens, CD/metabolism
MH  - Antigens, Differentiation, Myelomonocytic/metabolism
MH  - Chemokine CCL2/genetics/urine
MH  - Diabetes Mellitus, Experimental/complications/immunology
MH  - Diabetic Nephropathies/*drug therapy/*immunology/pathology
MH  - Dose-Response Relationship, Drug
MH  - Kidney/pathology
MH  - Macrophages/immunology/pathology
MH  - Male
MH  - Organ Size/drug effects
MH  - Pentoxifylline/*pharmacology
MH  - Proteinuria/drug therapy/immunology/pathology
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2009/11/19 06:00
MHDA- 2010/07/16 06:00
CRDT- 2009/11/19 06:00
PHST- 2009/11/19 06:00 [entrez]
PHST- 2009/11/19 06:00 [pubmed]
PHST- 2010/07/16 06:00 [medline]
AID - 10.1007/s10753-009-9167-6 [doi]
PST - ppublish
SO  - Inflammation. 2010 Jun;33(3):137-43. doi: 10.1007/s10753-009-9167-6.